Endocrinology. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles

By Albano C.  

Human Reproduction, Vol. 14, Iss. 6, 1999-06 ,pp. : 1426-1430

Oxford University Press

Access to resources Recommend Favorite

Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation

By CRongières-Bertrand  

Human Reproduction, Vol. 14, Iss. 3, 1999-03 ,pp. : 683-688

Oxford University Press

Access to resources Recommend Favorite

Reproductive endocrinology. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist

By Ragni Guido   Vegetti Walter   Baroni Elena   Colombo Michela   Arnoldi Mariangela   Lombroso Giancarlo  

Human Reproduction, Vol. 16, Iss. 11, 2001-11 ,pp. : 2258-2262

Oxford University Press

Access to resources Recommend Favorite

Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist?

By Lin Y  

Human Reproduction, Vol. 14, Iss. 4, 1999-04 ,pp. : 885-888

Oxford University Press

Access to resources Recommend Favorite

Case report. High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization

By de Jong D  

Human Reproduction, Vol. 13, Iss. 3, 1998-03 ,pp. : 573-575

Oxford University Press

Access to resources Recommend Favorite